Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Renato D. Lopes MD, PhD"'
Autor:
Eduardo Ramacciotti MD, PhD, Leandro B. Agati PhD, Roberto Augusto Caffaro MD, PhD, Giuliano G. Volpiani MD, Renato D. Lopes MD, PhD, Anthony J. Comerota MD, Jawed Fareed PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 25 (2019)
Direct oral anticoagulants (DOACs) are now widely used for the management of venous thromboembolism (VTE) that now includes cancer-associated thrombosis. This review summarizes recent data on VTE prophylaxis and treatment, new challenges, guidelines,
Externí odkaz:
https://doaj.org/article/31886d6b21ec4630961d797b7c05ea41
Autor:
Eduardo Ramacciotti MD, PhD, Leandro B. Agati PhD, Valéria C. R. Aguiar MD, Nelson Wolosker MD, PhD, João C. Guerra MD, PhD, Roque P. de Almeida MD, PhD, Juliana Cardoso Alves MD, Renato D. Lopes MD, PhD, Thomas W. Wakefield MD, Anthony J. Comerota MD, Jeanine Walenga PhD, Jawed Fareed PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 25 (2019)
A variety of viral infections are associated with hypercoagulable states and may be linked to the development of deep venous thrombosis and pulmonary embolism. The Zika and Chikungunya viral infections spread through the South and Central American co
Externí odkaz:
https://doaj.org/article/cb6d40a98a884ede8da3150135de779f
Autor:
Konstantin A. Krychtiuk, MD, PhD, Renato D. Lopes, MD, PhD, MHS, Daniel M. Wojdyla, MS, Shaun G. Goodman, MD, MSc, Ronald Aronson, MD, Stephan Windecker, MD, Roxana Mehran, MD, Christopher B. Granger, MD, John H. Alexander, MD, MHS, Karen P. Alexander, MD
Publikováno v:
JACC: Advances, Vol 3, Iss 11, Pp 101335- (2024)
Background: Patients with atrial fibrillation (AF) after an acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI) with multiple comorbidities are at increased risk for bleeding and ischemic events. Objectives: This
Externí odkaz:
https://doaj.org/article/65cf2f5f51084fe683a7538908098567
Autor:
John Eikelboom, MBBS, MSc, Sumathy Rangarajan, MSc, Sanjit S. Jolly, MD, Emilie P. Belley-Cote, MD, PhD, Richard Whitlock, MD, PhD, Heather Beresh, MSc, Gayle Lewis, Lizhen Xu, PhD, Noel Chan, MD, Shrikant Bangdiwala, PhD, Rafael Diaz, MD, Andres Orlandini, MD, Mohamed Hassany, MD, Wadea M. Tarhuni, MD, A.M. Yusufali, MD, Sanjib Kumar Sharma, MD, Anna Kontsevaya, PhD, Patricio Lopez-Jaramillo, MD, Alvaro Avezum, MD, Antonio L. Dans, MD, Sean Wasserman, MBChB, Camilo Felix, MD, Khawar Kazmi, MD, Prem Pais, MD, Denis Xavier, MD, Renato D. Lopes, MD, PhD, Otavio Berwanger, MD, Menelas Nkeshimana, MMed, William Harper, MD, Mark Loeb, MD, Shurjeel Choudhri, MD, Michael E. Farkouh, MD, Jackie Bosch, PhD, Sonia S. Anand, PhD, Salim Yusuf, DPhil
Publikováno v:
CJC Open, Vol 4, Iss 6, Pp 568-576 (2022)
Background: Effective treatments for COVID-19 are urgently needed, but conducting randomized trials during the pandemic has been challenging. Methods: The Anti-Coronavirus Therapy (ACT) trials are parallel factorial international trials that aimed to
Externí odkaz:
https://doaj.org/article/585b79616e5942cc97f1ad18f5a15a5f